Surya Patra: Okay, sure sir. Then sir the extended question relating to this that see the cash flow generation what we are witnessing. So, considering that, so, the near-term priorities — could you share the near-term priorities that you would be having? Because, what I have seen that you have already indicated that and you are likely to be — or you’re likely to remain active in terms of inorganic growth as well as the R&D spend also, rate, if I see, it has just moved on, along with the kind of ramp up in the revenues. So, considering these two things, what priorities that would be there for us in the next 12 to 15 months or 18 months’ period going ahead?
Erez Israeli: So, as we discussed in the past, our priority is productivity in the short-term. So, it needs to grow what we call Horizon 1 which is meaning the current business that we have, including investment in those productivity investment in our portfolio, in the ability to get some of those complex genetic faster to the market, some of those biosimilars faster to the market. As well in Horizon 2 building those new businesses that will give us the growth in the future. As we showed in the past, we assume that we will be able to generate enough cash and enough profit to finance for those activities and so far it is going well for us. The extra cash that we will have, we will use for business development and for investment in capabilities in the business, especially digital and mechanization, automation, and artificial intelligence.
The — and in line of what we have discussed, so I say the old guidance remain the same, we are comfortable on the long-term basis with the 25% EBITDA and 25% ROCE, double-digit growth and no debt. This continue to be the guidance that from time-to-time will be above it like this; from time to time, we’ll be below it like some couple quarters ago. But overall, I think it’s allow us to both to be very healthy company and to grow very, very well and we have potential upside even to exceed these numbers. But so far, we are very much into that, that makes up for the quarter, but if you see record for the last few years, we are very much where we said we are going to be.
Surya Patra: Sure sir. So, then the revenue — US revenue excluding REVLIMID, if you consider, we have seen this year as a kind of we all know we maintained the revenue run rate excluding REVLIMID. But there were challenges and a couple of our key products also witnessed competition from others largely from Indian players only. So, for this revenue piece, could you give some sense that okay next year, what is the visibility that you are having? Are you likely to see the sustained competition and all that impacting the business or some sense about growth that you can indicate for the US business excluding REVLIMID?
Erez Israeli: Next — in FY 2024, we are planning to launch at least 30 products give or take. And we are planning to continue the growth that we saw in the last couple of years. So, we indicated that we believe that the baseline of 6% — not 6%, that single-digit growth, 6% was the past. Single-digit growth will likely to happen and maybe more than that. And from time-to-time, we’ll have a product or products that will create much better growth. And that like I said to us in the last couple of months, and those products at a certain point in time also will go down with . So, overall, the trend is growing. In addition to that, we believe that once Horizon 2 will kick-in also the US will go in double-digit, but this is in a later stage towards five, six, seven years from now
